Picard Medical Q3: Going-Concern Warning With $67K Cash and Zero Product Revenue
PMI has more than doubled off its 52-week low of $2.652.
Summary
Picard Medical posted a $15.5 million nine-month net loss, held $67 thousand of cash, recorded zero product revenue in Q3, and disclosed substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · PMI
-
Going-Concern Warning Disclosed
Citing recurring operating losses and negative cash flow, management concluded there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the November 16, 2026 issuance date.
-
Cash Falls to $67 Thousand
Cash and cash equivalents stood at $67 thousand at September 30, 2026, versus $7,451 thousand at December 31, 2025; total current assets fell to $7.6 million from $20.7 million.
-
Zero Product Revenue in Q3
Q3 2026 product revenue was $0 versus $1.1 million a year earlier, and total revenue of $217 thousand — all from rentals — was down 82% from $1.187 million. Nine-month revenue rose 10% to $4.3 million.
-
Nine-Month Net Loss of $15.5 Million
For the nine months ended September 30, 2026, the net loss was $15.5 million, including a $10.2 million non-cash loss on settlement of debt and a $6.4 million non-cash fair-value gain on the senior secured note and warrant liability.
Analysis · PMI · Industrial Applications And Services
Management has flagged substantial doubt about Picard's ability to continue as a going concern for at least twelve months, with the company ending September 30, 2026 holding just $67 thousand of cash and $1.3 million of stockholders' equity. The quarter generated no product revenue at all; total revenue of $217 thousand came entirely from rentals, down 82% from $1.187 million a year earlier, while the nine-month net loss reached $15.5 million. Funding is now coming from small related-party and short-term loans, most debt has already been converted or settled into equity, and the company operates under an NYSE American compliance plan running to November 8, 2027. The sole offsetting item is management's forward-looking statement that confirmed orders should push Q4 product sales above the $0.9 million reported for Q4 2025 — a claim, not a booked result.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMI was trading at $7.24 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $17.8M. The 52-week trading range was $2.65 to $208.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.